Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation

Executive Summary

Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.

Advertisement

Related Content

Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments
Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach
Drug Pricing: National Academies Weighs In With Some Familiar Proposals
The Great Rebate Debate: Why Do They Exist?
Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS122135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel